Free Trial
OTCMKTS:ANTH

Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis

Anthera Pharmaceuticals logo
$0.0001
+0.00 (+∞)
(As of 11/1/2024 08:57 PM ET)

About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.0001
$0.0002
Volume
100 shs
Average Volume
6,757 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Receive ANTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ANTH Stock News Headlines

MACK - Merrimack Pharmaceuticals, Inc.
CRUSHED: How Biden's Replacement Will Devastate Your 401(k)!
Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.
See More Headlines

ANTH Stock Analysis - Frequently Asked Questions

Anthera Pharmaceuticals' stock was trading at $0.0001 at the start of the year. Since then, ANTH shares have increased by 0.0% and is now trading at $0.0001.
View the best growth stocks for 2024 here
.

Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) announced its quarterly earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.09.

Anthera Pharmaceuticals's stock reverse split on the morning of Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol-Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
3/05/2018
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:ANTH
Employees
20
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.97
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:ANTH) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners